Before you acquire a CLIA-certified lab, verify compliance, payer contracts, equipment health, and billing integrity — here's exactly what to review.
Acquiring an independent clinical laboratory or diagnostics company in the $1M–$5M revenue range requires far more scrutiny than a typical small business purchase. Regulatory licensing, Medicare reimbursement exposure, equipment lifecycle, and key-person dependency can each independently break a deal or destroy post-close value. This checklist covers the five highest-leverage due diligence categories specific to lab and diagnostics acquisitions, with red flags and priority ratings to help buyers allocate their time and protect their investment.
Verify the lab's standing with CLIA, CAP, state agencies, and federal oversight bodies before committing to any deal structure.
Obtain current CLIA certificate, confirm certificate type, expiration date, and scope of testing authorized.
An expired or misclassified CLIA certificate halts operations immediately and triggers CMS sanctions.
Red flag: CLIA certificate is expired, under probation, or does not cover all tests currently being performed.
Review CAP accreditation records, most recent inspection report, and any deficiency correction plans.
CAP accreditation signals quality standards and is often required by hospital and health system clients.
Red flag: Outstanding CAP deficiencies unresolved for more than 60 days or accreditation lapsed without renewal.
Pull full OIG exclusion database check on the lab entity, lab director, and all billing personnel.
A single OIG-excluded individual voids Medicare billing rights and triggers repayment obligations.
Red flag: Any current or prior OIG exclusion, CMS billing suspension, or Stark Law self-disclosure filing.
Confirm all required state laboratory licenses are current and identify change-of-ownership notification requirements by state.
Many states require separate licensure that does not automatically transfer upon sale of the business.
Red flag: State lab license cannot be assigned and requires re-application with a 90-plus day processing window.
Understand the revenue sustainability of every payer relationship, including exposure to rate cuts and contract assignment risk.
Collect all commercial, Medicare, and Medicaid payer contracts and map reimbursement rates by CPT code.
Reimbursement rates vary widely by payer and determine true revenue quality and margin durability.
Red flag: More than 50% of revenue is tied to Medicare fee schedule tests heavily impacted by PAMA rate reductions.
Identify change-of-ownership assignment clauses in every active payer contract and confirm assignability.
Payer contracts that terminate upon sale can eliminate revenue streams before post-close operations stabilize.
Red flag: One or more top-three payers require re-credentialing or new contract negotiation post-close with no guarantees.
Analyze contract renewal dates and flag any agreements expiring within 12 months of projected close date.
Near-term renewals expose buyers to renegotiation risk at the worst possible time during ownership transition.
Red flag: A payer representing over 20% of revenue has a contract expiring within six months of close with no renewal executed.
Request three years of payer mix trend data broken down by commercial, Medicare, Medicaid, and self-pay volumes.
Shifts toward government payers signal margin compression risk and indicate vulnerability to CLFS rate changes.
Red flag: Medicaid or Medicare mix has grown more than 15 percentage points in three years without corresponding volume growth.
Assess billing accuracy, collections performance, and coding integrity to avoid inheriting hidden compliance liabilities.
Request 36 months of denial rate reports by payer and CPT code category from the billing system.
Chronic high denial rates signal coding errors, credentialing gaps, or medical necessity documentation failures.
Red flag: Overall denial rate exceeds 10% or a single payer denial rate exceeds 15% without a documented remediation plan.
Review days sales outstanding by payer class and compare against industry benchmarks of 35–50 days for labs.
Elevated DSO indicates collections dysfunction and may signal underlying billing or contract performance issues.
Red flag: DSO exceeds 65 days on average or government payer DSO is trending upward over the prior four quarters.
Engage a healthcare billing compliance attorney to audit a sample of claims for upcoding, unbundling, or ABN violations.
Improper coding in lab billing is a primary trigger for CMS audits and False Claims Act exposure.
Red flag: Sample audit reveals systematic upcoding of molecular or pathology CPT codes without supporting clinical documentation.
Confirm that the lab uses compliant Advanced Beneficiary Notices and tracks medical necessity determinations for Medicare patients.
Missing ABNs force labs to absorb test costs and create retroactive Medicare repayment obligations.
Red flag: No formal ABN process exists or staff cannot demonstrate consistent application of medical necessity screening.
Evaluate the condition, ownership, and remaining useful life of all diagnostic analyzers, instruments, and IT systems.
Obtain a full equipment inventory with purchase dates, acquisition cost, current lease or ownership status, and vendor.
Undisclosed equipment leases transfer to the buyer and can carry significant payment obligations post-close.
Red flag: Multiple high-value analyzers are on expiring leases with unfavorable renewal terms or no purchase option.
Review all maintenance logs, calibration records, and service contracts for primary analyzers and instrumentation.
Poorly maintained equipment poses CLIA compliance risk and signals impending capital expenditure requirements.
Red flag: Calibration records are incomplete or analyzers are running past manufacturer recommended service intervals.
Commission an independent biomedical equipment assessment for any analyzer older than seven years or with high run volumes.
End-of-life equipment can require $250K–$1M in replacement capital within 24 months of acquisition.
Red flag: Independent assessment identifies two or more critical instruments requiring replacement within 18 months post-close.
Evaluate the laboratory information system version, interoperability with referring provider EHRs, and data migration feasibility.
Outdated LIS platforms create integration barriers with new referral sources and increase operational risk.
Red flag: LIS is running on an unsupported platform with no vendor upgrade path or active customer support agreement.
Quantify dependency on individual employees and referral sources that could destabilize operations after ownership transfer.
Review the lab director's CLIA qualifications, employment agreement terms, and stated intent post-acquisition.
Loss of the CLIA-qualified lab director post-close can trigger an immediate operations suspension by CMS.
Red flag: Lab director has no employment agreement in place and has expressed reluctance to stay beyond six months.
Build a referring provider concentration report showing top 10 accounts by specimen volume and tenure of relationship.
High concentration in one or two referral sources creates catastrophic revenue risk if those accounts leave.
Red flag: A single referring physician group or hospital represents more than 35% of total annual specimen volume.
Identify all certified medical laboratory scientists, pathologists, and specialty technicians and confirm licensure is current.
Shortages of credentialed lab staff make replacement extremely difficult and costly in the current labor market.
Red flag: More than two senior MLSs have departed in the past 12 months without documented succession or backfill.
Interview key referring physicians directly to assess relationship strength, satisfaction, and continuity expectations post-sale.
Physician relationships drive volume; if they are tied to the seller personally, revenue may not transfer.
Red flag: Referring physicians indicate their loyalty is to the current owner and they are actively evaluating alternative lab partners.
Find Lab & Diagnostics Company Businesses For Sale
Vetted targets with diligence packages — skip the cold search.
Expect 60–90 days for a thorough lab acquisition. Regulatory review of CLIA, CAP, and payer contracts alone typically requires 30–45 days, especially when state licensure transfer timelines and billing compliance audits are included. Asset purchases with escrow holdbacks tied to license transfer milestones can extend the overall timeline to close.
Yes, SBA 7(a) loans are commonly used for lab acquisitions in the $1M–$5M revenue range. Lenders will scrutinize CLIA compliance history, payer contract stability, and recurring revenue quality. A clean regulatory record with no open OIG or CMS audit issues is typically required for SBA credit approval, and lenders may require seller financing of 10–15% to demonstrate seller confidence in the transition.
In an asset purchase, the acquiring entity must enroll independently with CMS under a new Medicare provider number, which can take 60–120 days and interrupts Medicare billing during that window. A stock purchase preserves the existing Medicare enrollment but transfers all prior billing liability. Buyers should engage a healthcare attorney to evaluate which structure minimizes enrollment disruption while managing compliance exposure.
Focus on three indicators: the depth of referring provider relationships beyond the current owner, the assignability of top payer contracts, and the lab director's willingness to sign a multi-year employment agreement. Have the seller introduce you directly to the top five referring physicians before close. Volume retention clauses in earnout structures are a common way to align seller incentives with post-close revenue continuity.
More Lab & Diagnostics Company Guides
More Due Diligence Checklists
Stop cold-searching. Find signal-scored Lab & Diagnostics Company targets with seller motivation already identified.
Create your free accountNo credit card required
For Buyers
For Sellers